Email this article The analysis of secondary AA-amyloidosis current etiology and its influence on the approaches for diagnosis and treatment
- Authors: Rameev V.V.1, Kozlovskaya L.V.1, Rameeva A.S.1, Novikov A.V.1, Barsuk M.V.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Issue: Vol 93, No 6 (2021)
- Pages: 672-678
- Section: Original articles
- URL: https://journals.rcsi.science/0040-3660/article/view/75947
- DOI: https://doi.org/10.26442/00403660.2021.06.200851
- ID: 75947
Cite item
Full Text
Abstract
Aim. To investigate an influence of the currently changed etiologic structure of AA-amyloidosis on the diagnosis and treatment tactics.
Materials and methods. In 110 patients with АА-amyloidosis followed during full disease duration (1 month – 29 years) etiology, clinical manyfestations and approaches to diagnose and treatment of AA-amyloidosis were evaluated. With ELISA levels of amyloid precursor acute phase inflammation reactant SAA and neutrophil activity marker S100A12 were measured.
Results. Among the most common causes of AA-amyloidosis at the present stage, in addition to RA (40.3%), a significant place is occupied by a group of diseases with a predominantly autoinflammatory mechanism (53.73%). To confirm the autoinflammatory mechanism of the predisposing disease it is recommended to study a highly sensitive parameter serum protein S100A12. An effective marker of the risk of AA-amyloidosis progression, especially in patients with subclinical activity of inflammatory disease, is a high level of production of amyloidogenic protein-a precursor of SAA.
Full Text
##article.viewOnOriginalSite##About the authors
Vilen V. Rameev
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: vvrameev@mail.ru
ORCID iD: 0000-0003-4260-0226
д-р мед. наук, доц. каф. внутренних, профессиональных болезней и ревматологии
Russian Federation, MoscowLidiia V. Kozlovskaya
Sechenov First Moscow State Medical University (Sechenov University)
Email: vvrameev@mail.ru
ORCID iD: 0000-0002-1166-7308
д-р мед. наук, проф., проф. каф. внутренних, профессиональных болезней и ревматологии
Russian Federation, MoscowAnna S. Rameeva
Sechenov First Moscow State Medical University (Sechenov University)
Email: vvrameev@mail.ru
ORCID iD: 0000-0002-1040-723X
аспирант каф. внутренних, профессиональных болезней и ревматологии
Russian Federation, MoscowAleksandr V. Novikov
Sechenov First Moscow State Medical University (Sechenov University)
Email: gen.vkontakte@yandex.ru
ORCID iD: 0000-0001-9572-4818
студент Международной школы «Медицина будущего»
Russian Federation, MoscowMariia V. Barsuk
Sechenov First Moscow State Medical University (Sechenov University)
Email: mashabarsuk@mal.ru
ORCID iD: 0000-0002-2186-978X
студент Международной школы «Медицина будущего»
Russian Federation, MoscowReferences
- Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016;23(4):209-13. doi: 10.1080/13506129.2016.1257986
- Серов В.В., Шамов И.А. Амилоидоз. М.: Медицина, 1977 [Serov VV, Shamov IA. Amyloidosis. Moscow: Medicine, 1977 (in Russian)].
- Мухин Н.А. Амилоидоз почек: вопросы клиники и патогенеза: автореф. дис. … д-ра мед. наук. М., 1981; с. 41 [Mukhin NA. Amiloidoz pochek: voprosy kliniki i patogeneza: avtoref. dis. … d-ra med. nauk. Moscow: 1981; p. 41 (in Russian)].
- Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361-71. doi: 10.1056/NEJMoa070265
- Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013;161:525-32. doi: 10.1111/bjh.12286
- Айвазян А.А. Периодическая болезнь. Ереван: Айастан, 1982 [Ayvazyan AA. Periodic illness. Yerevan: Hayastan, 1982 (in Russian)].
- Piram M, Koné-Paut I, Lachmann HJ, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis. 2014;73(12):2168-73. doi: 10.1136/annrheumdis-2013-203666
- Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum. 2011;63(3):840-9. doi: 10.1002/art.30149
- van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH. Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria. Arthritis Rheum. 2011;63(1):37-42. doi: 10.1002/art.30100
- Mukhtyar C, Lee R, Brown D, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis. 2009;68(12):1827-32. doi: 10.1136/ard.2008.101279
- Martins NA, Furtado GE, Campos MJ, et al. Exercise and ankylosing spondylitis with New York modified criteria: a systematic review of controlled trials with meta-analysis. Acta Reumat Port. 2014;39(4):298-308
- Direskeneli H, Gül A. ISBD basic research perspectives. A preliminary “outline” for basic research workshop studies. Adv Exp Med Biol. 2003;528:293-99. doi: 10.1007/0-306-48382-3_59
- Mourgues C, Pereira B, Vorilhon P, et al. 2012 American guidelines for the management of gout as seen by general practitioners. Comment on GOSPEL 3: Management of gout by primary-care physicians and office-based rheumatologists in France in the early 21st century – comparison with 2006 EULAR Recommendations. Joint Bone Spine. 2018;1:1297-319. doi: 10.1016/j.jbspin.2018.09.015
Supplementary files
